Kiniksa Pharmaceuticals, Ltd. (KNSA) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
Connexa Pharmaceuticals (KNSA) Q2 2026: ARCLIS Revenue Jumps 55% as Penetration Hits 21%
July 28, 2026
-
Connexa (KNSA) Q1 2026: ARCLIS Revenue Jumps 56% as Prescriber Base Expands
April 28, 2026
-
KNSA Q4 2025: Arclist Penetration Reaches 18% as Market Expansion Accelerates
February 25, 2026
-
Connexa (KNSA) Q3 2025: Arcalyst Prescriber Base Expands by 350, Underpinning Guidance Hike
October 28, 2025
-
Conexa (KNSA) Q2 2025: ARCALYST Net Sales Raised $35M as Prescriber Base Expands
July 29, 2025
-
Connexa (KNSA) Q1 2025: Arclist Prescriber Base Expands by 300, Fueling 75% Revenue Surge
July 07, 2025